- Home
- RLAY vs BBNX Comparison
RLAY vs BBNX Comparison
Compare RLAY & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RLAY | BBNX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | RLAY | BBNX |
|---|---|---|
| Price | $7.81 | $17.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 12 |
| Target Price | $16.00 | ★ $29.75 |
| AVG Volume (30 Days) | ★ 2.3M | 1.2M |
| Earning Date | 02-25-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,355,000.00 | ★ $88,570,000.00 |
| Revenue This Year | $20.47 | $52.13 |
| Revenue Next Year | N/A | $36.16 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 67.01 |
| 52 Week Low | $1.78 | $8.89 |
| 52 Week High | $9.04 | $32.71 |
Technical Indicators
Market Signals| Indicator | RLAY | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 24.02 |
| Support Level | $7.85 | $28.36 |
| Resistance Level | $8.66 | $32.58 |
| Average True Range (ATR) | 0.41 | 1.99 |
| MACD | -0.11 | -1.30 |
| Stochastic Oscillator | 18.41 | 3.10 |
Price Performance
Historical ComparisonAbout RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.